Former BIO CEO Greenwood warns of “worst of times” for biopharma in Washington

As co-leader of a new life sciences policy and regulatory practice at DLA Piper, a law and lobbying firm, Jim Greenwood, former CEO and president of BIO and a former member of Congress, hopes to steer companies through what he expects to be a rocky political environment. 

“Six years ago, we thought it was the worst of times in terms of the political blowback and political pressure against the biotech industry, but it's worse now than it's ever been,” Greenwood told BioCentury. ...